TITLE

ABBVIE INC

PUB. DATE
July 2015
SOURCE
MondayMorning;7/27/2015, Vol. 23 Issue 27, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article offers information on AbbVie Inc., a research-based biopharmaceutical company. Topics discussed include the financial performance of the company, potential competition to face by the company over biotechnology company Amgen Inc., and the hepatitis C drug Viekira Pak is the second-biggest seller of the company.
ACCESSION #
108618119

 

Related Articles

  • AbbVie Beats Q3 Earnings Estimates, Raises Guidance. AMY REEVES // Investors Business Daily;10/31/2014, p00 

    Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63.

  • ABBVIE INC.  // MondayMorning;4/29/2013, Vol. 21 Issue 16, p1 

    The article reports on financial performance of the drugmaker AbbVie Inc. in the first quarter of 2013. It mentions that company has earned more profit than expected as its net income was 968 million U.S. dollars while revenue was 4.33 billion U.S. dollars for the same period. It informs that...

  • 2 Drugmakers Top Views, A 3rd Misses. AMY REEVES // Investors Business Daily;4/24/2015, pB06 

    The article focuses on the status and financial performances of drug manufacturers AbbVie and Novartis as of the first quarter (Q1) of 2015. It provides information on the companies' earnings per share (EPS), sales, and corporate profit. Also mentioned the drug development of Viekira and Humira...

  • AbbVie Beats Earnings Views, Sees Slower Humira Gain. AMY REEVES // Investors Business Daily;7/25/2014, p00 

    Big pharma

  • AbbVie Beats, But Stock Falls; Lilly Cuts Guidance. AMY REEVES // Investors Business Daily;1/30/2015, p00 

    The article reports on the finances of drugmakers AbbVie and Eli Lilly & Co. for the fourth quarter (Q4) of 2014. Topics discussed include the generated profit, shares, and revenue of both companies. Insights of analyst Michael Yee of RBC Capital Markets on the Phase III of AbbVie's drug...

  • Q3 Pharma Profits Mostly Miss. Investor's Business Daily // Investors Business Daily;11/10/2014, pB02 

    8

  • Earnings Rise At P&G Beauty Unit. Prior, Molly // WWD: Women's Wear Daily;10/28/2010, Vol. 200 Issue 89, p10 

    The article focuses on the financial performance of Procter & Gamble Co. in the first quarter of the financial year. As stated, for the first quarter that ended on September 30, 2010 the beauty unit's net earnings from continuing operations increased 7 percent to 829 million dollars and its...

  • ANGEION CORP REPORTS FISCAL 2010 4TH QTR $410,000 PROFIT.  // Biotech Financial Reports;Jan2011, Vol. 18 Issue 1, p7 

    The article reports on the financial performance of Angeion Corp. in the fourth quarter ended on October 31, 2010 in the U.S. Angeion earned a net profit of 410,000 dollars and revenues of 8.5 million dollars during the period. It mentions that the company's success is driven by expanded sales...

  • Anaren's quarterly profit climbs 41 percent. TAMPONE, KEBIN // Business Journal (Central New York);11/5/2010, Vol. 24 Issue 45, p4 

    The article offers information on the financial performance of Anaren Inc. in 2010. It states that its earnings increased by 41 percent to 4.1 million dollars in the first quarter as compared to the last year. It mentions that its earnings per share totaled 28 cents, an increase of 19 cents and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics